Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 May 2025 | Story André Damons | Photo Supplied
Prof Martin Nyaga
Prof Martin Nyaga, Full Professor in the Division of Virology and Head of the Next Generation Sequencing Unit (UFS-NGS Unit) at the University of the Free State.

Prof Martin Nyaga, an NRF B-Rated Full Professor in the Division of Virology and Head of the Next Generation Sequencing (UFS-NGS) Unit at the University of the Free State (UFS), has been selected as one of the cohort II fellows of the prestigious Calestous Juma Science Leadership Fellowship

Prof Nyaga, who is one of 12 individuals from six African countries (Ethiopia, Ghana, Kenya, Malawi, South Africa, and Zambia) selected to this cohort, says he is profoundly honoured. Through the prestigious fellowship, inspired by Professor Juma’s visionary legacy, he envisions advancing Africa’s capacity to combat infectious diseases by developing robust, mNGS-based surveillance systems that detect and characterise emerging pathogens early enough.

“The opportunity to join a cohort of exceptional African scientists, united by a shared commitment to addressing global health challenges, is both humbling and inspiring. I feel a deep sense of responsibility to uphold the fellowship’s mission of fostering sustainable development through cutting-edge research and policy engagement, particularly in the context of my work on genomic disease surveillance. 

“I am deeply inspired by Professor Calestous Juma’s legacy of harnessing science for sustainable development, and I am committed to embodying his optimism and interdisciplinary approach. The fellowship represents a transformative platform to advance scientific innovation and leadership in Africa. I would like to extend my gratitude to the Gates Foundation for this opportunity, and I look forward to contributing to a transformative era of African scientific leadership,” says Prof Nyaga.

 

Advantages of the Fellowship

The Calestous Juma Science Leadership Fellowship focuses on bringing together accomplished innovators to form a community of global health opinion shapers and influencers. The programme provides targeted professional development to support fellows as they expand their networks, amplify their voices, and continue to build and strengthen a dynamic, resilient research & development (R&D) ecosystem that changes the lives of people living not only in Africa but around the world.

Among the new cohort are experts in virology (including HIV and rota), bacteriology (including TB and strep), immunology, malaria, modelling, maternal immunisation, epidemiology, chemistry, drug discovery and development, vaccine discovery, clinical trials, and controlled human infection models to name just a few examples. 

According to Prof Nyaga, Director of a WHO Collaborating Centre for Vaccine Preventable Diseases (VPD) Surveillance and Pathogen Genomics, selection for the Fellowship is a rigorous and competitive process, designed to identify African scientists with exceptional research portfolios and leadership potential. Candidates are typically invited based on their established track record in transformative science, as well as their ability to anchor health and R&D initiatives within their communities. Successful applicants are evaluated for their scientific excellence, interdisciplinary networks, and commitment to mentoring the next generation of African scientists, aligning with the fellowship’s holistic view of leadership.

The NRF B3-rated scientist says he is eager to engage with the fellowship’s vibrant community of scientists from multiple African countries, fostering collaborations that amplify our collective impact on global health. He anticipates benefiting from the fellowship’s non-scientific training in communication, policy engagement, and institution strengthening. Participating in networking opportunities will broaden his perspectives and strengthen his capacity to drive innovative solutions in Africa’s genomic R&D ecosystem.

“I believe my work in pathogen surveillance research using genomics, aligns closely with the fellowship's objectives. As a fellow, I bring a wealth of experience in leading multi-country projects, establishing regional collaborations, and fostering capacity development through training and mentorship. 

“In addition, my ongoing work at the UFS-NGS Unit, including projects on enteric and respiratory virus surveillance, vaccine monitoring and efficacy using next generation sequencing, which will enrich discussions on public health. Conversely, the fellowship will enhance my scientific development by providing advanced training in leadership and policy advocacy, enabling me to translate research findings into actionable health policies. This synergy will elevate my capacity to lead transformative R&D initiatives and mentor future African scientists.” 

 

Contributing to the betterment of people 

Prof Nyaga believes his research on vaccine efficacy and metagenomics of gut and respiratory virome will contribute to the betterment of not only Africans, but also people around the world by informing targeted interventions in vaccine efficacy monitoring and development. This research will also contribute to the reduction of morbidity and mortality applicable to enteric and respiratory infections in vulnerable populations. 

Furthermore, he explains, the fellowship’s emphasis on networking and policy engagement will amplify these efforts, enabling him to advocate for evidence-based health policies across Africa. Globally, their collective work as Calestous Juma Science Leadership fellows will strengthen the R&D ecosystem, fostering innovation that addresses pandemic preparedness and other health challenges. By building resilient scientific communities, the fellowship will contribute to sustainable development, improving lives in Africa and beyond.

News Archive

Cochlear implant changes Magteld's world
2009-11-06

The microphone is ready for Magteld Smith’s (second from the left) first radio interview after the cochlear implant was switched on by Mr Henk Wolmarans (right) of MedEl. With them are, from the left: Ms Vicki Fourie, Deaf Miss SA, Ms Eunika Smith from the SABC and Prof. Jonathan Jansen.
Photo: Leatitia Pienaar


Magteld Smith gave her first steps towards the world of the hearing when her cochlear implant was switched on in the Universitas Hospital this week.

A whole team was there to share her joy and disbelief and amazement the moment she could hear noises, voices and conversations. Among them were the Rector and Vice-Chancellor of the University of the Free State (UFS), Prof. Jonathan Jansen, and the acting dean of the Faculty of Heath Sciences at the UFS, Prof. Gert van Zyl.

“I can hear my own voice! I haven’t heard it for a long time. My wish is that every deaf child can get something like this,” she said while prodding Prof. Jansen to speak so that she can hear his voice.

Magteld is working at the university's Centre for Health Systems Research and Development and was deaf since birth. She lost her last bit of hearing due to meningitis last year. Her hearing aids could then not assist her to communicate and a cochlear implant was the only option.

A donation by the Austrian company MedEl made the implant possible. Prof. André Claassen, Head of the Department of Otorhinolaryngology at the UFS, says MedEl was also instrumental in the establishment of the implant programme at the Universitas Hospital and sponsored the first five implants at a total cost of R1 million.

Prof. Claassen says 27 implants have already been done here, but it came to an abrupt halt due to a lack of funds. Strong hearing aids are expensive and cochlear implants are even more expensive at R200 000 each. People with hearing disabilities must be identified at an early age as the brain’s ability to learn sound and voice diminishes after the age of three.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept